Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly

Pituitary

Volumn 11, Issue 2, 2008, Pages 129-139

  Cazabat, Laure ^a   Souberbielle, Jean Claude ^b,c   Chanson, Philippe ^a,d  

^a BICÊTRE HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Acromegaly; Dynamic tests; Growth hormone; Insulin like growth factor 1; Octreotide test; Oral glucose tolerance test; Pituitary

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CORTICOTROPIN RELEASING FACTOR; GHRELIN; GONADORELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; PEGVISOMANT; PROTIRELIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACROMEGALY; AGE; ARTICLE; DIAGNOSTIC VALUE; DISEASE CONTROL; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GONADORELIN TEST; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; MORBIDITY; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTIRELIN TEST; RADIOIMMUNOASSAY; REMISSION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; THERAPY EFFECT; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT OUTCOME;

ACROMEGALY; AGING; FEMALE; GLUCOSE TOLERANCE TEST; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; MALE; OCTREOTIDE; PITUITARY FUNCTION TESTS; SOMATOSTATIN;

EID: 43049157987     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-008-0113-7     Document Type: Article

References (60)

1. Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529 Medline. doi: 10.1210/jc.85.2.526
2. Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab (2004) 89:3099-3102 Medline. doi: 10.1210/jc.2003-031138
3. Seth J, Ellis A, Al-Sadie R (1999) Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme. Horm Res 51(Suppl 1):13-19 Medline. doi: 10.1159/000053130
4. Baumann G (1999) Growth hormone heterogeneity in human pituitary and plasma. Horm Res 51(Suppl 1):2-6 Medline. doi: 10.1159/000053128
5. Wieringa GE, Barth JH, Trainer PJ (2004) Growth hormone assay standardization: A biased view? Clin Endocrinol (Oxf) 60:538-539 Medline. doi: 10.1046/j.1365-2265.2004.01982.x
6. Sheppard MC (2007) Growth hormone assay standardization: An important clinical advance. Clin Endocrinol (Oxf) 66:157-161 Medline. doi: 10.1111/ j.1365-2265.2007.02703.x
7. Trainer PJ, Barth J, Sturgeon C, Wieringaon G (2006) Consensus statement on the standardisation of GH assays. Eur J Endocrinol 155:1-2 Medline. doi: 10.1530/eje.1.02186
8. Bayle M, Chevenne D, Dousset B et al (2004) Recommandations pour la standardisation des dosages d'hormone de croissance. Ann Biol Clin (Paris) 62:155-163 Medline
9. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 67:65-70 Medline. doi: 10.1111/j.1365-2265.2007.02836.x
10. Ho KY, Evans WS, Blizzard RM et al (1987) Effects of sex and age on the 24-hour profile of growth hormone secretion in man: Importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64:51-58 Medline
11. Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693-721 Medline. doi: 10.1210/ er.2003-0035
12. Faria AC, Bekenstein LW, Booth RA Jr et al (1992) Pulsatile growth hormone release in normal women during the menstrual cycle. Clin Endocrinol (Oxf) 36:591-596 Medline
13. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO (1994) Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 78:1312-1319 Medline. doi: 10.1210/jc.78.6.1312
14. Markkanen H, Pekkarinen T, Valimaki MJ et al (2006) Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls. Clin Chem 52:468-473 doi: 10.1373/ clinchem.2005.060236
15. Freda PU, Landman RE, Sundeen RE, Post KD (2001) Gender and age in the biochemical assessment of cure of acromegaly. Pituitary 4:163-171 Medline. doi: 10.1023/A:1015314906972
16. Costa AC, Rossi A, Martinelli CE Jr, Machado HR, Moreira AC (2002) Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: Should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 87:3142-3147 Medline. doi: 10.1210/jc.87.7.3142
17. Freda PU, Post KD, Powell JS, Wardlaw SL (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808-3816 Medline. doi: 10.1210/jc.83.11.3808
18. Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P, Spada A (2007) Adequacy of current postglucose GH nadir limit (<1 microg/l) to define long-lasting remission of acromegalic disease. Clin Endocrinol (Oxf) 66:538-542 Medline
19. Trainer PJ (2002) Editorial: Acromegaly-consensus, what consensus? J Clin Endocrinol Metab 87:3534-3536 Medline. doi: 10.1210/jc.87.8.3534
20. Pekic S, Doknic M, Miljic D et al (2006) Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly. Eur J Endocrinol 154:659-666 Medline. doi: 10.1530/eje.1.02148
21. Grottoli S, Razzore P, Gaia D et al (2003) Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 26:123-127 Medline
22. Grottoli S, Gasco V, Ragazzoni F, Ghigo E (2003) Hormonal diagnosis of GH hypersecretory states. J Endocrinol Invest 26(Suppl):27-35 Medline
23. Hattori N, Shimatsu A, Kato Y et al (1990) Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J Clin Endocrinol Metab 70:771-776 Medline
24. Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740 Medline. doi: 10.1530/eje.1.02036
25. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: Implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542 Medline. doi: 10.1210/jc.87.8.3537
26. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Bruce JN (2003) Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary 6:175-180 Medline. doi: 10.1023/ B:PITU.0000023424.72021.e2
27. Freda PU (2003) Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 13:171-184 Medline. doi: 10.1016/S1096-6374(03)00029-7
28. Freda PU (2003) Pitfalls in the biochemical assessment of acromegaly. Pituitary 6:135-140 Medline. doi: 10.1023/B:PITU.0000011174.79946.10
29. Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernandez I et al (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62:293-299 Medline. doi: 10.1159/000082032
30. Parkinson C, Ryder WD, Trainer PJ (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240-5244 Medline. doi: 10.1210/jc.86.11.5240
31. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ (2002) Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 57:59-64 Medline. doi: 10.1046/j.1365-2265.2002.01560.x
32. Lim DJ, Kwon HS, Cho JH et al (2007) Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia. Endocr J 54:537-541 Medline. doi: 10.1507/endocrj.K06-083
33. Roelfsema V, Clark RG (2001) The growth hormone and insulin-like growth factor axis: Its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 12:1297-1306 Medline
34. Mussig K, Gallwitz B, Ranke MB, Horger M, Haring HU, Quabbe HJ (2006) Acromegaly and end-stage renal disease: A diagnostic challenge. J Endocrinol Invest 29:745-749 Medline
35. Wong NA, Ahlquist JA, Camacho-Hubner C et al (1997) Acromegaly or chronic renal failure: A diagnostic dilemma. Clin Endocrinol (Oxf) 46:221-226 Medline. doi: 10.1046/j.1365-2265.1997.960911.x
36. Colao A, Merola B, Ferone D et al (1994) Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: In vivo and in vitro studies. Eur J Endocrinol 131:14-19 Medline
37. Utsumi A, Hanew K, Sugawara A et al (1992) Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly-the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone. J Endocrinol Invest 15:167-171 Medline
38. Yang IM, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK (1995) Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf) 42:295-301 Medline
39. Park C, Yang I, Woo J et al (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 51:227-236 Medline. doi: 10.1507/endocrj.51.227
40. Pumarino H, Oviedo S, Michelsen H, Campino C (1991) [Active acromegaly and gigantism: Some clinical characteristics of 50 patients]. Rev Med Chil 119:897-907 Medline
41. Biermasz NR, Smit JW, van Dulken H, Roelfsema F (2002) Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clin Endocrinol (Oxf) 56:313-319 Medline. doi: 10.1046/j.1365-2265.2002.01465.x
42. Watanobe H, Tamura T (1995) A re-evaluation of the prolactin-releasing activity of growth hormone-releasing hormone in acromegaly in vivo. Neuropeptides 28:73-78 Medline. doi: 10.1016/0143-4179(95)90078-0
43. Watanobe H, Tamura T (1995) Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly. Neuropeptides 28:115-124 Medline. doi: 10.1016/ 0143-4179(95)90083-7
44. De Marinis L, Mancini A, Bianchi A et al (2002) Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients. Metabolism 51:616-621 Medline. doi: 10.1053/meta.2002.32017
45. Schaison G, Couzinet B, Moatti N, Pertuiset B (1983) Critical study of the growth hormone response to dynamic tests and the insulin growth factor assay in acromegaly after microsurgery. Clin Endocrinol (Oxf) 18:541-549 Medline
46. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89:495-500 Medline. doi: 10.1210/jc.2003-031316
47. Colao A, Pivonello R, Cavallo LM et al (2006) Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 65:250-256 Medline. doi: 10.1111/j.1365-2265.2006.02584.x
48. Minuto F, Resmini E, Boschetti M et al (2004) Assessment of disease activity in acromegaly by means of a single blood sample: Comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 61:138-144 Medline. doi: 10.1111/j.1365-2265.2004.02064.x
49. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G (2003) Evolving criteria for post-operative biochemical remission of acromegaly: Can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 10:611-619 Medline. doi: 10.1677/erc.0.0100611
50. Mukherjee A, Monson JP, Jonsson PJ, Trainer PJ, Shalet SM (2003) Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. J Clin Endocrinol Metab 88:5865-5870 Medline. doi: 10.1210/jc.2002-021741
51. Maison P, Chanson P (2006) Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk. Nat Clin Pract Endocrinol Metab 2:650-651 Medline. doi: 10.1038/ncpendmet0350
52. Brockmeier SJ, Buchfelder M, Fahlbusch R (1993) TRH/GnRH test in acromegaly. Long-term follow-up experience with successfully treated patients. Horm Metab Res 25:275-277 Medline
53. Chanson P (1997) Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? [comment]. Eur J Endocrinol 136:359-361 Medline
54. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res 15:200-206 Medline. doi: 10.1016/j.ghir.2005.02.007
55. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282-288 Medline. doi: 10.1111/j.1365-2265.2004.02191.x
56. Gilbert JA, Miell JP, Chambers SM, McGregor AM, Aylwin SJ (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxf) 62:742-747 Medline. doi: 10.1111/ j.1365-2265.2005.02278.x
57. Colao A, Ferone D, Lastoria S et al (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356-2362 Medline. doi: 10.1210/jc.81.6.2356
58. Lindsay JR, McConnell EM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB (2004) Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary 7:139-144 Medline. doi: 10.1007/s11102-005-1756-2
59. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153:67-71 Medline. doi: 10.1530/eje.1.01935
60. Pokrajac A, Claridge AG, Shakoor SK, Trainer PJ (2006) The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 154:267-274 Medline. doi: 10.1530/eje.1.02073